Alcon (SIX/NYSE:ALC), a global leader in eye care, announced its financial results for the second quarter and first half of 2024. In Q2 2024, the company achieved sales of $2.5 billion, marking a 3% increase on a reported basis and a 6% rise on a constant currency basis compared to the same period last year. Alcon reported diluted earnings per share of $0.45 and core diluted earnings per share of $0.74 for the quarter.
“We are pleased with our solid second-quarter results, driven by strong demand for our innovative products, a well-balanced geographic footprint, and effective team execution. These factors contributed to growth in sales, earnings, and cash generation,” said David J. Endicott, CEO of Alcon. “As we move into the second half of the year, we will focus on preparing for upcoming product launches that will set the stage for our next phase of growth in 2025 and beyond.”
Key Figures for Q2 and First Half of 2024
Three Months Ended June 30
- Net Sales: $2.48 billion, up 3% reported and 6% in constant currency.
- Operating Margin: 12.8%, compared to 11.2% in Q2 2023.
- Diluted EPS: $0.45, up from $0.34 in Q2 2023.
- Core Operating Margin: 19.8%, compared to 19.9% in Q2 2023.
- Core Diluted EPS: $0.74, compared to $0.69 in Q2 2023.
- Net Cash Flows from Operating Activities: $871 million, compared to $410 million in Q2 2023.
- Free Cash Flow: $667 million, up from $189 million in Q2 2023.
Six Months Ended June 30
- Net Sales: $4.93 billion, up 4% reported and 7% in constant currency.
- Operating Margin: 13.9%, compared to 11.4% in H1 2023.
- Diluted EPS: $0.95, up from $0.69 in H1 2023.
- Core Operating Margin: 20.9%, compared to 20.3% in H1 2023.
- Core Diluted EPS: $1.52, compared to $1.39 in H1 2023.
Sales by Segment
Surgical
- Total: $1.42 billion in Q2 2024, up 3% reported and 6% in constant currency.
- Implantables: $464 million, up 6% (9% in constant currency).
- Consumables: $736 million, up 3% (5% in constant currency).
- Equipment/Other: $223 million, down 3% (1% in constant currency).
Vision Care
- Total: $1.06 billion in Q2 2024, up 4% reported and 6% in constant currency.
- Contact Lenses: $636 million, up 7% (9% in constant currency).
- Ocular Health: $423 million, down 1% (2% in constant currency).
